Published in Women's Health Weekly, April 4th, 2002
The company is requesting Priority Review, having received Fast Track Designation for this submission on December 21, 2001, from the FDA based on data from the ATAC (Arimidex and Tamoxifen, Alone or in Combination) study, the largest breast cancer treatment trial ever conducted. Arimidex is currently approved in the U.S. for use in advanced breast cancer in postmenopausal women. The FDA grants Priority Review status for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly